ADB-5'Br-BUTINACA (ADB-B-5Br-INACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug,[1] first detected in Philadelphia in the US in May 2022,[2] and subsequently found in South Korea,[3] Portugal and Sweden.[4] It is specifically listed as an illegal drug in Italy,[5] South Korea[6] and several states in the US,[7][8] and controlled under analogue legislation in various other jurisdictions.
^Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, McKenzie C, Gréen H, Stove CP (October 2023). "In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs". Drug Testing and Analysis. doi:10.1002/dta.3592. PMID37903509. S2CID264671035.
^"ADB-5'Br-BINACA"(PDF). CFSRE Chemistry Report. The Center for Forensic Science Research & Education.
^Kim J, Yum H, Kang S, Lee N, Song J, Park Y, Choe S, Park M (November 2023). "Comprehensive evaluation of drug cases in Seoul and its metropolitan areas - 2022". Forensic Science International. 353: 111877. doi:10.1016/j.forsciint.2023.111877. PMID37989071. S2CID265022768.
^"˝에이디비-5'비알-부티나카˝ 등 3종 임시마약류 지정예고" [Announcement of temporary designation of 3 types of narcotics, including “ADB-5 ‘BR-Butinaka’”]. Korean Food and Drug Daily News (in Korean).